Organon Reports Positive Six — Year Interim Phase 3 Results for Miudella IUD

Organon announced positive interim Phase 3 results showing contraceptive efficacy for its hormone-free copper IUD, MIUDELLA, through six years. Bleeding- and pain-related discontinuations declined over time; reported adverse events included heavy menstrual bleeding, menstrual pain and pelvic discomfort. Sebela Women's Health will present the findings October 17, 2026, at the Society of Family Planning Annual Meeting in San Francisco. The FDA accepted an application to extend use to six years, with a decision expected in the second quarter of 2027. Currently indicated for three years, MIUDELLA was exclusively licensed globally from Sebela Women's Health in June 2026. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Organon & Co. published the original content used to generate this news brief via (Ref. ID: 20261016500412) on October 16, 2026, and is solely responsible for the information contained therein. (C)